These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 20511137)

  • 1. The clinical application of UGT1A1 pharmacogenetic testing: gene-environment interactions.
    Marques SC; Ikediobi ON
    Hum Genomics; 2010 Apr; 4(4):238-49. PubMed ID: 20511137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer.
    Araki K; Fujita K; Ando Y; Nagashima F; Yamamoto W; Endo H; Miya T; Kodama K; Narabayashi M; Sasaki Y
    Cancer Sci; 2006 Nov; 97(11):1255-9. PubMed ID: 16965601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics and irinotecan therapy.
    Hahn KK; Wolff JJ; Kolesar JM
    Am J Health Syst Pharm; 2006 Nov; 63(22):2211-7. PubMed ID: 17090741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetic approach for cancer treatment-tailored medicine in practice.
    Hasegawa Y; Ando Y; Ando M; Hashimoto N; Imaizumi K; Shimokata K
    Ann N Y Acad Sci; 2006 Nov; 1086():223-32. PubMed ID: 17185519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet?
    Perera MA; Innocenti F; Ratain MJ
    Pharmacotherapy; 2008 Jun; 28(6):755-68. PubMed ID: 18503403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism.
    Iyer L; Hall D; Das S; Mortell MA; Ramírez J; Kim S; Di Rienzo A; Ratain MJ
    Clin Pharmacol Ther; 1999 May; 65(5):576-82. PubMed ID: 10340924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics of irinotecan: a promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan.
    Ando M; Hasegawa Y; Ando Y
    Invest New Drugs; 2005 Dec; 23(6):539-45. PubMed ID: 16267624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question.
    Deeken JF; Slack R; Marshall JL
    Cancer; 2008 Oct; 113(7):1502-10. PubMed ID: 18720361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. UGT1A1, UGT1A6 and UGT1A7 genetic analysis: repercussion for irinotecan pharmacogenetics in the São Miguel Island Population (Azores, Portugal).
    Pacheco PR; Brilhante MJ; Ballart C; Sigalat F; Polena H; Cabral R; Branco CC; Mota-Vieira L
    Mol Diagn Ther; 2009; 13(4):261-8. PubMed ID: 19712005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene and irinotecan toxicity.
    Kitagawa C; Ando M; Ando Y; Sekido Y; Wakai K; Imaizumi K; Shimokata K; Hasegawa Y
    Pharmacogenet Genomics; 2005 Jan; 15(1):35-41. PubMed ID: 15864124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.
    Ando Y; Saka H; Ando M; Sawa T; Muro K; Ueoka H; Yokoyama A; Saitoh S; Shimokata K; Hasegawa Y
    Cancer Res; 2000 Dec; 60(24):6921-6. PubMed ID: 11156391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping.
    Innocenti F; Ratain MJ
    Pharmacogenomics; 2006 Dec; 7(8):1211-21. PubMed ID: 17184208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicities.
    Fakih MG; Ross ME; Starostik P
    Clin Colorectal Cancer; 2007 Jul; 6(8):583-7. PubMed ID: 17681105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Genetics External Quality Assessment Pilot Scheme for Irinotecan-Related UGT1A1 Genotyping in China.
    Yi L; Lin G; Zhang K; Wang L; Zhang R; Xie J; Li J
    PLoS One; 2016; 11(1):e0148081. PubMed ID: 26820647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uridine diphosphate glucuronosyltransferase 1A1.
    Steventon G
    Xenobiotica; 2020 Jan; 50(1):64-76. PubMed ID: 31092094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.
    Iyer L; Das S; Janisch L; Wen M; Ramírez J; Karrison T; Fleming GF; Vokes EE; Schilsky RL; Ratain MJ
    Pharmacogenomics J; 2002; 2(1):43-7. PubMed ID: 11990381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38.
    Paoluzzi L; Singh AS; Price DK; Danesi R; Mathijssen RH; Verweij J; Figg WD; Sparreboom A
    J Clin Pharmacol; 2004 Aug; 44(8):854-60. PubMed ID: 15286088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irinotecan treatment in cancer patients with UGT1A1 polymorphisms.
    Innocenti F; Ratain MJ
    Oncology (Williston Park); 2003 May; 17(5 Suppl 5):52-5. PubMed ID: 12800608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. UGT1AI*6 and UGT1A1*27 for individualized irinotecan chemotherapy.
    Ando Y; Fujita K; Sasaki Y; Hasegawa Y
    Curr Opin Mol Ther; 2007 Jun; 9(3):258-62. PubMed ID: 17608024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphisms of UGT1A1*6, UGT1A1*27 & UGT1A1*28 in three major ethnic groups from Malaysia.
    Teh LK; Hashim H; Zakaria ZA; Salleh MZ
    Indian J Med Res; 2012 Aug; 136(2):249-59. PubMed ID: 22960892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.